Geron Corporation Receives U.S. Patent for Stem Cell Culture Medium
MENLO PARK, Calif.--(BUSINESS WIRE)--Nov. 7, 2003--Geron
Corporation (Nasdaq:GERN) announced today that it has been granted
U.S. Patent No. 6,642,048, by the U.S. Patent and Trademark office.
The patent includes claims that cover methods and compositions for
growing human embryonic stem cells (hESCs) using cell-free conditioned
medium.
"This new patent addresses an important part of our efforts to
scalably produce hESCs for commercial use," said Thomas B. Okarma,
Ph.D., M.D., Geron's president and chief executive officer. "We have
developed a way to scale up hESC production by eliminating the use of
mouse feeder cells in the hESC culture system. This advance enables
the scalable production of hESCs using standard reagents and
conditions, criteria important for regulatory approval of our cell
production process."
Geron is a biopharmaceutical company focused on developing and
commercializing therapeutic and diagnostic products for cancer based
on its telomerase technology, and cell-based therapeutics using its
human embryonic stem cell technology. |
